Cronos Group Inc.

CRON

$3.27

+0.15%

2026-09-04 10:32:09 EDT+$0.01

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and ...

Price Action of CRON

$3.27

+0.15%+$0.01

High—

Low—

52W High-9.4%

Rel. vol—

Interval

Range62m

Volume—SMA5SMA10

—

Cronos Group Inc. (NASDAQ: CRON) is a cannabinoid-focused company that operates across the cannabis value chain, including cultivation, production, distribution, and marketing. The company’s core strategic theme is building and scaling consumer-facing cannabinoid products supported by research and product innovation. In the United States, Cronos develops, markets, and supplies hemp-derived ...Cronos Group Inc. (NASDAQ: CRON) is a cannabinoid-focused company that operates across the cannabis value chain, including cultivation, production, distribution, and marketing. The company’s core strategic theme is building and scaling consumer-facing cannabinoid products supported by research and product innovation. In the United States, Cronos develops, markets, and supplies hemp-derived wellness and beauty offerings, while it also produces and commercializes cannabis and related extracts for both therapeutic and adult-use consumption. On the product side, Cronos markets cannabis offerings that can include dried flower, pre-rolled joints, edibles, concentrates, and other extracts. These products are distributed through a mix of wholesale channels and direct-to-consumer/online channels. The company also exports cannabis products and oils to international markets such as Germany, Israel, and Australia, which helps diversify revenue sources and supports its global footprint. Cronos’ brand architecture includes consumer wellness/beauty offerings and dedicated adult-use branding. The provided company description indicates hemp-derived wellness and beauty products are marketed under the Lord Jones and Happy Dance brands, while its wellness segment is aligned with the PEACE NATURALS platform and adult-use products are marketed through the Spinach brand. Such brand segmentation supports tailored positioning across different regulatory regimes and consumer needs. From an operational and cost perspective, cannabinoid manufacturing typically involves cultivation and processing capacity, extraction/production workflows, quality control, packaging, logistics, and marketing expenses to sustain brand demand. Cronos’ business model also requires navigating regulatory requirements and supply-chain constraints common to cannabis markets, which can affect working capital and inventory levels. Financially, the company’s valuation metrics and cash-flow-related ratios (as available in the provided data) suggest it operates with meaningful margins and active operating cash-flow generation (with enterprise value and profitability/margin measures provided on a TTM basis). Key people: Michael Ryan Gorenstein serves as Chairman, President, and Chief Executive Officer. The company was founded in 2012 and is headquartered in Toronto, Canada. Overall, Cronos positions itself as an “innovation + consumer goods scaling” cannabinoid company—aiming to translate product development and intellectual-property building into recurring consumer demand through recognizable brands and multi-channel distribution.ExpandCollapse

Founded

2012

Employees

610

CEO

Michael Ryan Gorenstein

Full Name

Cronos Group Inc.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

ROE

6.46%

Market Cap

$1.20B

Current Ratio

16.18

WACC

10.35%

ROIC

2.73%

Contact Information

https://www.thecronosgroup.com

14165040004

4491 Concession Road 12, Stayner, ON L0M 1S0

Key Metrics of CRON

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.20B

ROCE

0.0%

EV / EBITDA

13.90x

+1.6% YoY

FCF Yield

4.1%

+4.1% YoY

Cash Conversion Cycle

248.0d

Current Ratio

16.18

Quick take

TTM —

Positive CCC

Financial Highlights of CRON

Profitability trend

Latest / TTM · 6 periods

Gross Margin

45.4%

Net Margin

38.9%

P/E Ratio

17.36x

n/a

Debt / Equity

0.00

n/a

Current Ratio

16.18

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of CRON

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.03 · Revenue $49.47M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.03 · Revenue $60.33M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.16 · Revenue $199.00M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.00 · Revenue $52.80M

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $0.08 · Revenue $70.60M
View filing
May 11, 2026
Q1 FY2026 · Results reported
EPS $0.04 · Revenue $44.58M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-0.03 · Revenue $149.15M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $0.07 · Revenue $36.34M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-0.10 · Revenue $33.45M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $0.02 · Revenue $32.26M
View filing

Financial Statements of CRON

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$149.2M	+26.8%	+58.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-9.6M	-123.4%	+136.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+41.4%	+93.1%	-2.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-12.0%	+81.6%	+425.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-6.4%	-118.5%	+49.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$151611	-97.3%	+91.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+0.1%	-97.9%	+21.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.1%	-27.3%	-0.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	19.59x	+4.0%	-26.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.2B	+2.6%	+0.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.03 vs -0.00	-904.0%	0.08 vs 0.01	+733.0%
Revenue Surprise	$149.2M vs $138.8M	+7.4%	$70.6M vs $44.2M	+59.7%

Insider Transactions of CRON

Acquisitions (A)

Since May 12, 2026

Disposals (D)

Since May 12, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 6, 2026	Garnick Murray R	director	DEFERRED SHARE UNITS	A	48,860	—
Aug 6, 2026	RUDYK JAMES DANIEL	director	DEFERRED SHARE UNITS	A	48,860	—
Aug 6, 2026	ADLER JASON MARC	director	DEFERRED SHARE UNITS	A	48,860	—
Jun 18, 2026	Broughton Darren Chester	director:	—	—	0	—
May 12, 2026	Doucet Terrence Gregory Joseph	officer: See Remarks	RESTRICTED STOCK UNITS	D	10,597	—

Earnings Call Transcript of CRON

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning. My name is Hailey, and I will be your conference operator today. I would like to welcome everyone to Cronos' 2026 Second Quarter Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Harrison Aaron, Senior Director of Investor Relations and Corporate Development. Please go ahead. Harrison Aaron: Thank you, Hailey, and thank you for joining us today to review Cronos' 2026 Q2 financial and business performance. Today, I'm joined by our Chairman, President, and CEO, Mike Gorenstein, and our CFO, Anna Shlimak. Cronos issued a news release announcing our financial results this morning, which is filed on our EDGAR and SEDAR profiles. This information and the prepared remarks will also be posted on our website under Investor Relations. Before I turn the call over to Mike, let me remind you that we may make forward-looking statements and refer to non-GAAP financial measures during this call. These forward-looking statements are based on management's current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Factors that cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, by which any forward-looking statements made during this call are qualified in their entirety. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials that are available on our website. Lastly, we will be making statements regarding market share information throughout this conference call, and unless otherwise stated, all market share data is provided by Hifyre. We will now make prepared remarks, and then we'll move to a question-and-answer session. With that, I'll pass it over to Cronos' Chairman, President, and CEO, Mike Gorenstein. Michael Gorenstein: Thanks, Harrison. Cronos delivered a stellar second quarter, organically achieving records across net revenue, gross profit, and adjusted EBITDA, as our borderless product strategy continues to gain momentum across each region in which we operate. Yesterday, the Trade Levies Commissioner of the Israeli Ministry of Economy and Industry announced that it had opened a new investigation into alleged dumping of medical cannabis imports from Canada. This announcement follows the previous investigation by the Commissioner, which did not result in the imposition of an anti-dumping duty. We dispute the allegations underlying the investigation. We will cooperate fully with the ministry and are confident the facts support us. Our position has not changed. Cronos does not engage in dumping. During the last investigation of these same allegations, we provided the Trade Commissioner with comprehensive pricing and cost data that demonstrated that our pricing in the Israeli market …

Leadership Team of CRON

9 executives

Name	Title	Compensation	Gender	Year Born	Status
Michael Ryan Gorenstein	President, Chief Executive Officer & Chairman	USD 2,134,125	Male	1987	Active
Anna Shlimak	Chief Financial Officer	USD 795,480	Female	1986	Active
Jeffrey David Jacobson	Chief Growth Officer	USD 765,870	Male	1986	Active
Adam Wagner	General Manager of Cronos Israel	USD 637,214	Male	1983	Active
Shannon Buggy	Senior Vice President & Global Head of People	USD 530,015	Female	1970	Active
Terry Gregory-Joseph Doucet	General Counsel & Corporate Secretary	—	Male	1990	Active
Harrison Aaron	Senior Director of Investor Relations & Corporate Development	—	Male	—	Active
Arye Weigensberg	Senior Vice President and Head of Research & Development	—	Male	1983	Active
Jared Matthew Kenost	Principal Accounting Officer, Vice President & Controller	—	Male	—	Active

Recent News of CRON

Zacks Investment Research8/20/2026Neutral

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research8/18/2026Neutral

Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

CNBC8/15/2026Neutral

Marijuana reform is emerging as a midterm elections issue on both sides of the aisle

With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.

Seeking Alpha8/7/2026Neutral

Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts

Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.

Seeking Alpha8/7/2026Neutral

Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A

Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.

Historical Employee Count of CRON

Current

610

Change

+32.90%

Minimum

356

Maximum

626

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	610	10-K	Feb 26, 2026	View
Dec 31, 2024	459	10-K	Feb 27, 2025	View
Dec 31, 2023	356	10-K	Feb 29, 2024	View
Dec 31, 2022	447	10-K	Feb 28, 2023	View
Dec 31, 2021	626	10-K	Mar 1, 2022	View

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Cronos Group Inc.